Endothelial cell responses to hypoxic stress

Clinical and Experimental Pharmacology and Physiology

Volumn 26, Issue 1, 1999, Pages 74-84

  Faller, Douglas V ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Activating protein 1; Endothelin 1; Nitric oxide; Oxygen; Platelet derived growth factor; Thrombospondin 1; Vascular endothelial growth factor; Vascular smooth muscle; Vasoconstriction

Indexed keywords

ENDOTHELIN 1; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX PROTEIN; NITRIC OXIDE; PLATELET DERIVED GROWTH FACTOR B; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; VASCULOTROPIN; VASOACTIVE AGENT;

ATHEROSCLEROSIS; BLOOD FLOW; BLOOD VESSEL TONE; CELL PROLIFERATION; CONFERENCE PAPER; DNA BINDING; ENDOTHELIUM CELL; FEEDBACK SYSTEM; GENE EXPRESSION; GENE INDUCTION; HYPOXIA; OXYGEN TENSION; PULMONARY HYPERTENSION; SCLERODERMA; SICKLE CELL ANEMIA; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TRANSCRIPTION REGULATION; VASOCONSTRICTION;

CELL HYPOXIA; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; GROWTH SUBSTANCES; HUMANS; OXYGEN; TRANSCRIPTION, GENETIC;

EID: 0032891180     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.1999.02992.x     Document Type: Conference Paper

References (176)

1. 1. Gerritsen ME, Bloor CM. Endothelial cell gene expression in response to injury. FASEB J. 1993; 7: 523-32.
2. 2. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 1990; 186: 1-85.
3. 3. Smith P. Ultrastructure of the lung in chronic hypoxia. Thorax 1994; 49: S27-32.
4. 4. Meyrick B, Reid L. Hypoxia-induced structural changes in the media and adventitia of the rat hilar pulmonary artery and their regression. Am. J. Pathol 1980; 100: 151-78.
5. 5. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
6. 6. Holden WE, McCall E. Hypoxia-induced contractions of porcine pulmonary artery strips depends on intact endothelium. Exp. Lung Res. 1984; 7: 101-12.
7. 7. Nelin LD, Rickaby DA, Linehan JH, Dawson CA. The vascular site of action of hypoxia in the neonatal pig lung. Pediatr. Res. 1994; 35: 25-9.
8. 8. Rubanyi GM, Vanhoutte PM. Hypoxia releases a vasoconstrictor substance from the canine vascular endothelium. J. Physiol. 1985; 364: 45-56.
9. 9. Vender RL, Clemmons DR, Kwock L, Friedman M. Reduced oxygen tension induces pulmonary endothelium to release a pulmonary smooth muscle cell mitogen(s). Am. Rev. Respir. Dis. 1987; 135: 622-7.
10. 10. Rakugi H, Tabuchi Y, Nakamaru M et al. Evidence for endothelin-1 release from resistance vessels of rats in response to hypoxia. Biochem. Biophys. Res. Commun. 1990; 169; 973-7.
11. 11. Shirakami G, Nakao K, Saito Y et al. Acute pulmonary alveolar hypoxia increases lung and plasma endothelin-1 levels in conscious rats. Life Sci. 1991; 48: 969-76.
12. 12. Vane JR, Anggard EE, Botting RM. Mechanisms of disease: Regulatory functions of the vascular endothelium. N. Engl. J. Med. 1990; 323: 27-36.
13. 13. Kourembanas S, Hannan R, Faller DV. Oxygen tension regulates the expression of platelet-derived growth factor-B chain gene in human endothelial cells. J. Clin. Invest. 1990; 86: 670-4.
14. 14. Kourembanas S, Marsden PA, Mcquillan LP, Faller DV. Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J. Clin. Invest. 1991; 88: 1054-7.
15. 15. Hannan R, Kourembanas S, Flanders K et al. Endothelial cells synthesize basic fibroblast growth factor and transforming growth factor beta. Growth Factors 1988; 1: 7-17.
16. 16. Kourembanas S, McQuillan LP, Leung GK, Faller DV. Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxic and hypoxic conditions. J. Clin. Invest. 1993; 92: 99-104.
17. 17. Kourembanas S, Faller DV. Platelet-derived growth factor production by human umbilical vein endothelial cells is regulated by basic fibroblast growth factor. J. Biol. Chem. 1989; 264: 4456-9.
18. 18. Yoshimoto S, Ishizaki Y, Sasaki T, Murota S. Effect of carbon dioxide and oxygen on endothelin production by cultured porcine cerebral endothelial cells. Stroke 1991; 22: 378-83.
19. 19. Hieda H, Gomez-Sanchez C. Hypoxia increases endothelin release in bovine endothelial cells in culture, but epinephrine, norepinephrine, serotonin, histamine and angiotensin II do not. Life Sci. 1990; 247: 247-51.
20. 20. Vanhoutte PM, Auch-Schwelk W, Boulanger C et al. Does endothelin-1 mediate eudothelium-dependent contractions during anoxia? J. Canliovasc. Pharmacol. 1989; 13: S124-8.
21. 21. Joseph P, Thompson B, Hales C. Effect of hypoxia on the secretion of platelel derived growth factor by bovine pulmonary artery endothelial cells. Am. Rev. Respir. Dis. 1990; 141: A346 (Abstract).
22. 22. Goldberg MA, Dunning SP, Bunn HF. Regulation of the erythropoietin gene: Evidence that the oxygen sensor is a heme protein. Science 1988; 242: 1412-15.
23. 23. Lacombe C, Da Silva J, Bruneval P et al. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J. Clin. Invest. 1988; 81: 620-3.
24. 24. Goldberg MA, Glass GA, Cunningham JM, Bunn HF. The regulated expression of erythropoietin by two hepatoma cell lines. Proc. Natl Acad. Sci. USA 1987; 84: 7972-6.
25. 25. Rubler S, Fleischer RA. Sickle cell states and cardiomyopathy: Sudden death due to pulmonary thrombosis and infarction. Am. J. Cardiol. 1967; 19: 867-73.
26. 26. Oppenheimer EH, Esterly JR. Pulmonary changes in sickle cell disease. Am. Rev. Respir. Dis. 1971; 103: 858-9.
27. 27. Berk BC, Alexander RW, Brock TA, Gimbrone MA, Webb RC. Vasoconstriction: A new activity for platelet-derived growth factor. Science 1986; 32: 87-9.
28. 28. Sachinidis A, Locher R, Vetter W, Tatje D. Hoppe J. Different effects of platelet-derived growth factor isoforms on rat vascular smooth muscle cells. J. Biol. Chem. 1990; 265: 10238-43.
29. 29. Majack RA, Majesky MW, Goodman LV. Role of PDGF-A expression in the control of vascular smooth muscle cell growth by transforming growth factor-beta. J. Cell Biol. 1990; 111: 239-48.
30. 30. Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia: Modulation of gene expression by nitric oxide. J. Clin. Invest. 1995; 95: 1798-807.
31. 31. Waltenberger J, Mayr U, Pentz S, Hombach V. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation 1996; 94: 1647-54.
32. 32. Plate KH, Breier G, Millauer B, Ullrich A, Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. 1993; 53: 5822-7.
33. 33. Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-15.
34. 34. Li H, Elton TS, Chen YF, Oparil S. Increased endothelin receptor gene expression in hypoxic rat lung. Am. J. Physiol. 1994; 266: L553-60.
35. 35. Li HB, Chen SJ, Chen YF et al. Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia. J. Appl Physiol. 1994; 77: 1451-9.
36. 36. Elton TS, Oparil S, Taylor GR et al. Normobaric hypoxia stimulates endothelin-1 gene expression in the rat. Am. J. Physiol. 1992; 263: R1260-4.
37. 37. Katayose D, Ohe M, Yamauchi K et al. Increased expression of PDGF A-chain and B-chain genes in rat lungs with hypoxic pulmonary hypertension. Am. J. Physiol 1993; 264: L100-6.
38. 38. Martinet Y, Rom WR, Grotendorst GR. Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 1987; 317: 202-9.
39. 39. Ferri C, Bellini C, Deangelis C et al. Circulating endothelin-1 concentrations in patients with chronic hypoxia. J. Clin. Pathol 1995; 48: 519-24.
40. 40. Gay S, Jones J, Huang G, Gay RE. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and sis-oncogene expression in scleroderma. J. Invest. Dermatol 1989; 92: 301-3.
41. 41. Ferris JA, Falanga V, Leitzel KE. Elevated plasma platelet-derived growth factor β chain levels in scleroderma patients. Arthritis Rheum. 1990; 33: S64 (Abstract).
42. 42. Ignarro LJ, Byrns RE, Buga CM, Woods KS. Endothelium-derived relaxing factor from pulmonary artery and vein possessed pharmacologic and chemical properties identical to those of nitric oxide radical. Circ. Res. 1987; 61: 866-79.
43. 43. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-6.
44. 44. Garg UC, Hassid A. Nitric-oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of culture rat smooth muscle cells. J. Clin. Invest. 1989; 83: 1774-7.
45. 45. Garg UC, Hassid A. Nitric oxide-generating vasodilators inhibit mitogenesis and proliferation of BALB/c 3T3 fibroblasts by a cyclic GMP-independent mechanism. Biochem. Biophys. Res. Commun. 1990; 171: 474-9.
46. 46. Nakaki T, Nakayama M, Kato R. Inhibition by nitric oxide and nitric oxide-producing vasodilators of DNA synthesis in vascular smooth muscle cells. Eur. J. Pharmacol. 1990; 189: 347-53.
47. 47. Nathan C, Xie Q. Regulation of biosynthesis of nitric oxide. J. Biol. Chem. 1994; 269: 13725-8.
48. 48. Ignarro LJ, Burke TM, Wood KS, Wolin MS, Kadowitz PJ. Association between cyclic GMP accumulation and acetylcholine-elicited relaxation of bovine intrapulmonary artery. J. Pharmacol. Exp. Ther. 1984; 228: 682-90.
49. 49. Fiscus RR. Molecular mechanisms of endothelium-mediated vasodilation. Semin. Thromb. Hemostasis 1988; 14: 12-22.
50. 50. Phelan MW, Faller DV. Hypoxia decreases constitutive nitric oxide synthase transcript and protein in cultured endothelial cells. J. Cell Physiol. 1996; 167: 469-76.
51. 51. Archer SL, Freude KA, Shultz PJ. Effect of graded hypoxia on the induction and function of inducible nitric oxide synthase in rat mesangial cells. Circ. Res. 1995; 77: 21-8.
52. 52. Shaul PW, North AJ, Brannon TS et al. Prolonged in vivo hypoxia enhances nitric oxide synthase type I and type III gene expression in adult rat lung. Am. J. Respir. Cell Mol. Biol 1995; 13: 167-74.
53. 53. Pohl U, Busse R. Hypoxia stimulates release of endothelium-derived relaxant factor. Am. J. Physiol. 1989; 256: H1595-600.
54. 54. Xue C, Rengasamy A, Lecras TD, Koherna PA, Dailey GC, Johns RA. Distribution of NOS in normoxic vs hypoxic rat lung: Upregulation of NOS by chronic hypoxia. Am. J. Physiol. 1994; 11: L667-78.
55. 55. Le Cras TD, Xue C, Rengasamy A, Johns RA. Chronic hypoxia upregulates endothelial and inducible NO synthu.se gene and protein expression in rat lung. Am. J. Physiol. 1996; 14 L164-70.
56. 56. Hwang SM, Wilson PD, Laskin JD, Denhardt DT. Age and development-related changes in osteopontin and nitric oxide synthase mRNA levels in human kidney proximal tubule epithelial cells: Contrasting responses to hypoxia and reoxygenation. J. Cell Physiol. 1994; 160: 61-8.
57. 57. Lockhart A, Saiag B. Altitude and the human pulmonary circulation. Clin. Sci. 1981; 60: 599-605.
58. 58. Orton E, Reeves J, Stenmark K. Pulmonary vasodilation with structurally altered pulmonary vessels and pulmonary hypertension. J. Appl. Physiol. 1988; 65: 2459-67.
59. 59. Rabinovitch M, Konstam M, Gamble W et al. Changes in pulmonary blood flow affect vascular response to chronic hypoxia in rats. Circ. Res. 1983; 52: 432-41.
60. 60. Stenmark K, Fasules J, Voelkel N et al Severe pulmonary hypertension and arterial adventitial changes in newborn calves at 4300 m. J. Appl. Physiol. 1987; 62: 821-30.
61. 61. DeMichiels C, Leener F, Arnould T, Dieu M, Remacle J. Hypoxia stimulates human endothelial cells to release smooth muscle cell mitogens: Role of prostaglandins and BFGF. Exp. Cell Res. 1994; 213: 43-54.
62. 62. Zamora MR, StelznerTJ, Webb S, Panos RJ, Ruff LJ, Dempsey EC. Overexpression of endothelin-1 and enhanced growth of pulmonary artery smooth muscle cells from fawn-hooded rats. Am. J. Physiol. 1996; 14: L101-9.
63. A receptor antagonist, inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells. Am. J. Respir. Cell Mol. Biol 1993; 9: 429-33.
64. 64. Perkett E, Badesch D, Roessler M, Stenmark K, Meyrick B. Insulin-like growth factor-1 and pulmonary hypertension induced by continuous airembolization in sheep. Am. Rev. Respir. Dis. 1992; 6: 82-7.
65. 65. Shweiki D, Neeman M, Itin A, Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis. Proc. Natl Acad. Sci. USA 1995; 92: 768-72.
66. 66. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-5.
67. 67. Schmedtje JF, Ji YS, Liu WL, DuBois RN, Runge MS. Hypoxia induces cyclooxygenase-2 via the NF-kappa B p65 transcription factor in human vascular endothelial cells. J. Biol. Chem. 1997; 272: 601-8.
68. 2+ mobilization, by cAMP and GMP in rabbit aortic smooth muscle cells. Biochem. J. 1992; 288: 527-32.
69. 69. Benitz, W, Kelley R, Anderson C, Lorant D, Bernfield M. Endothelial heparan sulfate proteoglycan. I. Inhibitory effects on smooth muscle cell proliferation. Am. J. Respir. Cell Mol Biol. 1990; 2: 13-24.
70. 70. Humphries D, Lee S, Fanburg B, Silbert J. Effects of hypoxia and hyperoxia on proteoglycan production by bovine pulmonary artery endothelial cells. J. Cell Physiol. 1986; 126: 249-53.
71. 71. Leung DW, Cachianes G, Kuang W-J, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-8.
72. 72. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrine Rev. 1992; 13: 18-32.
73. 73. Namiki A, Brogi E, Kearney M et al. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J. Biol. Chem. 1995; 270: 31189-95.
74. 74. Stavri GT, Hong Y, Zachary IC et al. Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells. FERS Lett. 1995; 358: 311-15.
75. 75. Goldherg MA, Schneider TJ. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J. Biol. Chem. 1994; 269: 4355-9.
76. 76. Takagi H, King GL, Ferrara N, Aiello LP. Hypoxia regulates vascular endothelial growth factor receptor KDR/Flk gene expression through adenosine A(2) receptors in retinal capillary endothelial cells. Invest. Ophthalmol. Vis. Sci. 1996; 37: 1311-21.
77. 77. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J. Biol. Chem. 1995; 270: 13333-40.
78. 78. Minchenko A, SalcedaS, Bauer T, Caro J. Hypoxia regulatory elements of the human vascular endolhelial growth factor gene. Cell. Mol. Biol. Res. 1994; 40: 35-9.
79. 79. Liu YX, Cox SR, Morita T, Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells: Identification of a 5' enhancer. Circ. Res. 1995; 77: 638-43.
80. 80. Shima DT, Deutsch U, Damore PA. Hypoxic induction of vascular endothelial growth factor (VEGF) in human epithelial cells is mediated by increases in mRNA stability. FEBS Lett. 1995; 370: 203-8.
81. 81. Stein I, Neeman M, Shweiki D, Itin A, Keshet E. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol. Cell. Biol. 1995, 15: 5363-8.
82. 82. White FC, Carroll SM, Kamps MP. VEGF mRNA is reversibly stabilized by hypoxia and persistently stabilized in VEGF-overexpressing human tumor cell lines. Growth Factors 1995; 12:289-301.
83. 83. Vairo G, Innes KM, Adams JM. Bc1-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene 1996; 13: 1511-19.
84. 84. Gnarra JR, Zhou SB, Merrill MJ et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc. Natl Acad. Sci. USA 1996; 93: 10589-94.
85. 85. Lynch D, Ansell P, Levene R. Effect of anoxia on gene expression in human endothelial cells. J. Cell Biol. 1988; 107: 581A (Abstract).
86. 86. Baenziger NL, Brodie GN, Majerus PW. Isolation and properties of a thrombin-sensitive protein in human platelets. J. Biol Chem. 1972; 247: 2723-31.
87. 87. Baenziger NL, Brodie GN, Majerus PW. A thrombin-sensitive protein of human platelet membranes. Proc. Natl Acad. Sci. USA 1971; 68: 240-3.
88. 88. Frazier WA. Thrombospondins. Curr. Opin. Cell Biol. 1991 ; 3: 792-9.
89. 89. Mosher DF. Physiology of thrombospondin. Annu. Rev. Med. 1990; 41: 85-97.
90. 90. Mumby SM, Abbot-Brown GL, Bornstein P. Regulation of thrombospondin secretion by cells in culture. J. Cell Physiol. 1984; 120: 280-8.
91. 91. Dixit VM, Haverstick DM, O'Rourke KM et al. A monoclonal antibody against human thrombospondin inhibits platelet aggregation. Proc. Natl Acad. Sci. USA 1985; 82: 3472-6.
92. 92. O'Shea KS, Dixit VM. Unique distribution of the extracellular matrix component thrombospondin in the developing mouse embryo. J. Cell Biol. 1988; 107:2737-48.
93. 93. Good DJ, Polverini PJ, Rastinejad F et al. A tumor suppressor dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc, Natl Acad. Sci. USA 1990; 87: 6624-8.
94. 94. Phelan MW, Forman LW, Faller DV. Regulated expression of thrombospondin-1 gene expression and release by hypoxia in cultured endothelial cells. J. Lab. Clin. Med. 1998 (in press).
95. 95. Majack RA, Milbrant J, Dixit VM. Induction of thrombospondin messenger RNA levels occurs as a immediate primary response to platelet-derived growth factor. J. Biol. Chem. 1987; 262: 8821-5.
96. 96. Shima DT, Deutsch U, D'Amore PA. Hypoxic induction of vascular endothelial growth in human epithelial cells is mediated by increases in mRNA stability. Fed. Eur. Biochem. Soc. 1995; 370: 203-8.
97. 97. Ryseck R-P, Hirai SI, Yaniv M, Bravo R. Transcriptional activation of c-jun-1 during the G0/G1 transition in mouse fibroblasts. Nature 1988; 334: 535-7.
98. 98. Zubiaga AM, Munoz E, Huber BT. Superinduction of IL-2 gene transcription in the presence of cyclohexamide. J. Immunol. 1991; 146: 3857-63.
99. 99. Faller DV, Weng HQ, Choi SY. Activation of collagenase IV gene expression and enzymatic activity by the Moloney leukemia virus Long Terminal Repeat. Virology 1997; 227: 331-42.
100. 100. Bandyopadhyay RS, Phelan M, Faller DV. Hypoxia induces AP-1-regulated genes and AP-1 transcription factor binding in human endothelial and other cell types. Biochem. Biophys. Acta Gene Struct. Express 1995; 1264: 72-8.
101. 101. Bandyopadhyay RS, Faller DV. Regulation of c-jun gene expression in endothelial cells by the protein kinase inhibitor staurosporine. Endothelium 1997; 5: 95-105.
102. 102. Himelstein BP, Koch CJ. Studies of type IV collagenase regulation by hypoxia. Cancer Lett. 1998; 124: 127-33.
103. 103. Stevens T, Rodman DM. The effect of hypoxia on endothelial cell function. Endothelium 1995; 3: 1-12.
104. 104. Bunn HF, Poyton RO. Oxygen sensing and molecular adaptation to hypoxia. Physiol. Rev. 1996; 76: 839-85.
105. 105. Marshall C, Cooper D, Marshall B. Reduced availability of energy initiates pulmonary vasoconstriction. Proc. Soc. Exp. Biol. Med. 1988; 187: 282-6.
106. 106. Sylvester J, McGowan C. The effects of agents that bind to cytochrome P-450 on hypoxic pulmonary vasoconstriction. Circ. Res. 1978; 43: 429-37.
107. 2 sensor in the rat carotid body. FEBS Lett. 1989; 265: 75-8.
108. 108. Gleadle JM, Ebert BL, Ratcliffe PJ. Diphenylene iodonium inhibits the induction of erythropoietin and other mammalian genes by hypoxia: Implications for the mechanism of oxygen sensing. Eur. J. Biochem. 1995; 234: 92-9.
109. 109. Phelan M, Perrine SP, Brauer M, Faller DV. Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. J. Clin. Invest. 1995; 96: 1145-51.
110. 110. Kouremhanas S, Faller DV. Oxygen tension regulates the expression of the platelet-derived growth factor-B chain and endothelin genes in human endothelial cells. Semin. Perinatol. 1991; 5: 346-50.
111. 111. Mukhopadhyay D, Tsiokas L, Zhou X-M, Foster D, Brugge JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995; 375: 577-81.
112. 112. Wang GL, Jiang BH, Semenza GL. Effect of protein kinase and phosphatase inhibitors on expression of hypoxia-inducible factor 1. Biochem. Biophys. Res. Commun. 1995; 216: 669-75.
113. 113. Seko Y, Tobe K, Takahashi N, Kaburagi Y, Kadowaki T, Yazaki Y. Hypoxia and hypoxia/reoxygenation activate Src family tyrosine kinases and p21 (ras) in cultured rat cardiac myocytes. Biochem. Biophys. Res. Commun. 1996; 226: 530-5.
114. 114. Grugel S, Finkenzeller G, Weindel K, Barleon B, Marme D. Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol. Chem. 1995; 270: 25915-19.
115. 115. Lander HM, Ogiste JS, Pearce SFA, Levi R, Novogrodsky A. Nitric oxide-stimulated guanine nucleotide exchange on p21 (ras). J. Biol. Chem. 1995; 270: 7017-20.
116. 116. Hannun YA. The sphingomyelin cycle and the second messenger function of ceramide. J. Biol. Chem. 1994; 269: 3125-8.
117. 117. Kolesnick R, Golde DW. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell 1994; 77: 325-8.
118. 118. Rothendler J, Bandyopadhyay RS, Faller DV. Hypoxia activates the ceramide signaling pathway in endothelial cells. J. Lab. Clin. Med. 1998 (in press).
119. 119. Faller DV. Hypoxia, nitric oxide and vasoactive gene transcription. In: Parkinson J (ed.). Nitric Oxide, Cytochrome P450 and Sexual Steroid Hormones. Springer-Verlag, New York. 1997; 75-116.
120. 120. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-Ioop-helix-PAS heterodimer regulated by cellular O-2 tension. Proc. Natl Acad. Sci. USA 1995; 92: 5510-14.
121. 121. Maxwell PH, Pugh CW, Ratcliffe PJ. Inducible operation of the erythropoietin 3' enhancer in multiple cell lines: Evidence for a widespread oxygen-sensing mechanism. Proc. Natl Acad. Sci. USA 1993; 90: 2423-7.
122. 122. Yao KS, Xanthoudakis S, Curran T, O'Dwyer PJ. Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia. Mol Cell Biol. 1994; 14: 5997-6003.
123. 1-phase checkpoint by low-oxygen conditions is independent of p53 status. Mol. Cell Biol. 1994; 14: 6264-77.
124. 124. Koong AC, Chen EY, Giaccia AJ. Hypoxia causes the activation of Nuclear Factor-kappa-B through the phosphorylation of I-kappa-B alpha on tyrosine residues. Cancer Res. 1994; 54: 1425-30.
125. 125. Yao KS, O'Dwyer PJ. Involvement of NF-kappa B in the induction of NAD(P)H quinone oxidoreductase (DT-diaphorase) by hypoxia, oltipraz and mitomycin C. Biochem. Pharmacol. 1995; 49: 275-82.
126. 126. Benjamin IJ, Kroger B, Williams RS. Activation of the heat shock transcription factor by hypoxia in mammalian cells. Proc. Natl Acad. Sci. USA 1990; 87: 6263-7.
127. 127. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the human erythropoietin gene. Proc. Natl Acad. Sci. USA 1991; 88: 5680-4.
128. 128. Schmedtje JF, Liu WL, Ji YS, Thompson TM, Runge MS. Evidence of hypoxia-inducible factor-1 in vascular endothelial and smooth muscle cells. Biochem. Biophys. Res. Commun. 1996; 220: 687-91.
129. 129. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol Chem. 1994; 269: 23757-63.
130. 130. Eyssen Hemandez R, Ludoux A, Frelin C. Differential regulation of cardiac heme oxygenase-1 and vascular endothelial growth factor mRNA expressions by hemin, heavy metals, heat shock and anoxia. FEBS Lett. 1996; 382: 229-33.
131. 131. Lee M, Dhadly MS, Temizer DH, Clifford JA, Yoshizumi M, Quertermous T. Regulation of endothelin-1 gene expression by fos and jun. J. Biol. Chem. 1991; 266: 19034-9.
132. 132. Finkenzeller G, Technau A, Marme D. Hypoxia-induced transcription of the vascular endothelial growth factor gene is independent of functional AP-1 transcription factor. Biochem. Biophys. Res. Commun. 1995; 208: 432-9.
133. 133. Pech M, Rao CD, Robbins KC, Aaronson SA. Functional identification of regulatory elements within the promoter region of platelet-de-rived growth factor 2. Mol. Cell Biol. 1989; 9: 396-105.
134. 134. MeyerM, Pahl HL, Baeuerle PA. Regulation of the transcription factors NF-kappa B and AP-1 by redox changes. Chem. Biol. Interact. 1994; 91: 91-100.
135. 2 and antioxidants have opposite effects on activation of nf-kappa-b and ap-1 in intact cells: AP-1 as secondary antioxidant-responsive factor. EMBO J. 1993; 12: 2005-15.
136. 136. Toledano MB, Leonard WJ. Modulation of transcription factor NF-kappa B binding activity by oxidation-reduction in vitro. Proc. Natl Acad. Sci. USA 1991; 88: 4328-32.
137. 137. Ausserer WA, Bourratfloeck B, Green CJ, Laderoute KR, Sutherland RM. Regulation of c-jun expression during hypoxic and low-glucose stress. Mol. Cell Biol. 1994; 14: 5032-42.
138. 138. Webster KA, Discher DJ, Bishopric NH. Regulation of fos and jun immediate-early genes by redox or metabolic stress in cardiac myocytes. Circ. Res. 1994; 74: 679-86.
139. 139. Abate C, Patel L, Rauscher FJ, Curran T. Redox regulation of fos and jun DNA-binding activity in vitro. Science 1990; 249: 1157-61.
140. 140. Bannister AJ, Cook A, Kouzarides T. In vitro DNA binding activity of Fos/Jun and BZLF1 but not C/EBP is affected by redox changes. Oncogene 1991; 6: 1243-50.
141. 141. Frame MC, Wilkie NM, Darling AJ et al. Regulation of AP-1/DNA complex formation in vitro. Oncogene 1991; 6: 205-9.
142. 142. Laderoute KR, Calaoagan JM, Mendonca HL et al. Early responses of SiHa human squamous carcinoma cells tohypoxic signals: Evidence of parallel activation of NF-kappa B and AP-1 transcriptional complexes. Int. J. Oncol. 1996; 8: 875-82.
143. 143. Sen CK, Packer L. Antioxidant and redox regulation of gene transcription. FASEB J. 1996; 10: 709-20.
144. 144. Thanos D, Maniatis T. NF-kκB: A lesson in family values. Cell 1995; 80: 529-32.
145. 145. Koong AC, Chen EY, Mivechi NF, Denko NC, Stannhrook P, Giaccia AJ. Hypoxie activation of nuclear factor-kappa B is mediated by a Ras and Raf signaling pathway and does not involve MAP kinase (ERK1 or ERK2). Cancer Res. 1994; 54: 5273-9.
146. 146. Rupec RA, Baeuerle PA. The genomic response of tumor cells to hypoxia and reoxygenation: Differential activation of transcription factors AP-1 and NF-kappa B. Eur. J. Biochem. 1995; 234: 632-40.
147. 147. Fishman AP. Hypoxia on the pulmonary circulation. Circ. Res. 1976; 38: 221-31.
148. 148. Faller DV. Vascular Modulation in sickle cell anemia. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH (eds). Sickle Cell Disease: Basic Principles and Clinical Practice. Raven Press Ltd, New York. 1994; 235-46.
149. 149. Peacock AJ, Dawes KE, Shock A, Gray AJ, Reeves JT, Laurent GJ. Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts. Am. J. Respir. Cell Mol. Biol. 1992; 7: 492-9.
150. 150. Seppa H, Grotendorst G, Seppa S, Sciffman E, Martin GR. Platelet-derived growth factor is chemotactic for fibroblasts. J. Cell Biol. 1982; 92: 584-8.
151. 151. Dzau VJ, Gibbons GH. Endothelium and growth factors in vascular remodeling of hypertension. Hypertension 1991; 18: 115-21.
152. 152. Takuwa N, Takuwa Y, Yanagisawa M, Yamashita K, Masaki T. A novel vasoactive peptide endothelin stimulates mitogenesis through inositol lipid turnover in Swiss 3T3 fibroblasts. J. Biol Chem. 1989; 264: 7856-61.
153. 153. Komuro I, Kurihara H, Sugiyama T, Takaku F, Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett. 1988; 238: 249-52.
154. 154. Bobik A, Grooms A, Millar JA, Mitchell A, Grinpukel S. Growth activity of endothelin on vascular smooth muscle. Am. J. Physiol. 1990; 258: C408-15.
155. 155. Dawes KE, Peacock AJ, Gray AJ, Bishop JE, Laurent GJ. Characterization of fibroblast mitogens and chemoattractants produced by endothelial cells exposed to hypoxia. Am. J. Respir. Cell Mol. Biol. 1994; 10: 552-9.
156. 156. Nunokawa Y, Tanaka S. Interferon-gamma inhibits proliferation of rat vascular smooth muscle cells by nitric oxide generation. Biochem. Biophys. Res. Commun. 1992; 188: 409-15.
157. 157. Scott-Burden T, Schini VB, Elizondo E, Junquero DC, Vanhoutte PM. Platelet-derived growth factor suppresses and fibroblast growth factor enhances cytokine-induced production of nitric oxide by cultured smooth muscle cells: Effects on cell proliferation. Circ. Res. 1992; 71: 1088-100.
158. 158. Sarkar R, Webb RC, Stanley JC. Nitric oxide inhibition of endothelial cell mitogenesis and proliferation. Surgery 1995; 118: 274-9.
159. 159. Lau YT, Ma WC. Nitric oxide inhibits migration of cultured endothelial cells. Biochem. Biophys. Res. Commun. 1996; 221: 670-4.
160. 160. Kariya K, KawaharaY, Araki S, Fukuzaki H, Takai Y. Antiproliferative action of cyclic GMP elevating vasodilators in cultured rabbit aortic smooth muscle cells. Atherosclerosis 1989; 80: 143-7.
161. 161. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 1995; 333: 214-21.
162. 162. Moreland LW, Huang G, Gay R. Immunohistologic demonstration of platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) in scleroderma (SCL) skin. Arthritis Rheum. 1990; 33: S36 (Abstract).
163. 163. Blann AD, Illingworth K, Jayson M. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J. Rheumatol. 1993; 20: 1325-30.
164. 164. Campbell PM, LeRoy EC. Pathogenesis of systemic sclerosis: A vascular hypothesis. Semin. Arthritis Rheum. 1975; 4: 351-68.
165. 165. Trojanowski M, Wu L, LeRoy EC. Elevated expression of c-myc proto-oncogene in scleroderma fibroblasts. Oncogene 1988; 3: 477-81.
166. 166. Feghali CA, Bost KL, Boulware DW, Levy LS. Mechanism of pathogenesis in scleroderma: I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J. Rheumatol. 1992; 19: 1207-11.
167. 167. Silverstein JL, Steen VD, Medsger Jr TA, Falanga V. Cutaneous hypoxia in patients with systemic sclerosis (scleroderma). Arch. Dermatol. 1988; 124: 1379-82.
168. 168. Smiley JD. The many faces of scleroderma. Am. J. Med. Sci. 1992; 304: 319-33.
169. 169. Piasecki C, Chin J, Greenslade L, McIntyre N, Burroughs AK, McCormick PA. Endoscopic detection of ischaemia with a new probe indicates low oxygenation of gastric epithelium in portal hypertensive gastropathy. Gut 1995; 36: 654-6.
170. 170. Voelkel NF, Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur. Respir. J. 1995; 8: 2129-38.
171. 171. Sugihara K, Sugihara T, Mohandas N, Hebbel RP. Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells. Blood 1992; 80: 2634-42.
172. 172. Brittain HA, Echman JR, Swerlick RA, Howard RJ, Wick TM. Thrombospondin from activated platelets promotes sickle erythrocyte adherence to human microvascular endothelium under physiologic flow: A potential role for platelet activation in sickle cell vaso-occlusion. Blood 1993; 81: 2137-43.
173. 173. Hillery CA, Du MC, Montgomery RR, Scott JP. Increased adhesion of erythrocytes to components of the extracellular matrix: Isolation and characterization of a red blood cell lipid that binds thrombospondin and laminin. Blood 1996; 87: 4879-86.
174. 174. Ginis I, Mentzer SJ, Faller DV. Hypoxia induces lymphocyte adhesion to human mesenchymal cells via an LFA-1 -dependent mechanism. Am. J. Physiol. 1993; 264: C617-24.
175. 175. Ginis I, Mentzer SJ, Li XP, Faller DV. Characterization of a hypoxia-responsive adhesion molecule for leukocytes on human endothelial cells. J. Immunol. 1995; 155: 802-10.
176. 176. Ginis I, Mentzer SJ, Faller DV. Oxygen tension regulates neutrophil adhesion to human endothelial cells via an LFA-1-dependent mechanism. J. Cell Physiol. 1993; 157: 569-78.